Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.

CONCLUSIONS: pRCC and chRCC are rare but similarly fatal compared to ccRCC when advanced or metastatic. With most clinical trials devoted toward ccRCC, greater efforts to identify aggressive variants and treatment strategies for metastatic pRCC and chRCC are necessary. PMID: 31174958 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31174958?dopt=Abstract

Source: Urologic Oncology - June 4, 2019 Category: Urology & Nephrology Authors: Kaldany A, Paulucci DJ, Kannappan M, Beksac AT, Anastos H, Okhawere K, Sfakianos JP, Badani KK Tags: Urol Oncol Source Type: research